TY - JOUR KW - Alzheimer's disease KW - Amyloid PET KW - Cerebrospinal fluid KW - Monocentric KW - Preclinical KW - SUVR KW - Subjective memory complainers KW - Synergistic KW - Tau protein KW - ?-Synuclein ID - discovery10059341 N2 - INTRODUCTION: Several neurodegenerative brain proteinopathies, including Alzheimer's disease (AD), are associated with cerebral deposition of insoluble aggregates of ?-synuclein. Previous studies reported a trend toward increased cerebrospinal fluid (CSF) ?-synuclein (?-syn) concentrations in AD compared with other neurodegenerative diseases and healthy controls. METHODS: The pathophysiological role of CSF ?-syn in asymptomatic subjects at risk of AD has not been explored. We performed a large-scale cross-sectional observational monocentric study of preclinical individuals at risk for AD (INSIGHT-preAD). RESULTS: We found a positive association between CSF ?-syn concentrations and brain ?-amyloid deposition measures as mean cortical standard uptake value ratios. We demonstrate positive correlations between CSF ?-syn and both CSF t-tau and p-tau181 concentrations. DISCUSSION: Animal models presented evidence, indicating that ?-syn may synergistically and directly induce fibrillization of both tau and ?-amyloid. Our data indicate an association of CSF ?-syn with AD-related pathophysiological mechanisms, during the preclinical phase of the disease. TI - Association of Cerebrospinal Fluid ?-synuclein With Total and Phospho-tau181 Protein Concentrations and Brain Amyloid Load in Cognitively Normal Subjective Memory Complainers Stratified by Alzheimer's Disease Biomarkers EP - 1631 AV - public Y1 - 2018/12// JF - Alzheimers Dement A1 - Vergallo, A A1 - Bun, R-S A1 - Toschi, N A1 - Baldacci, F A1 - Zetterberg, H A1 - Blennow, K A1 - Cavedo, E A1 - Lamari, F A1 - Habert, M-O A1 - Dubois, B A1 - Floris, R A1 - Garaci, F A1 - Lista, S A1 - Hampel, H A1 - INSIGHT-preAD study group A1 - Alzheimer Precision Medicine Initiative (APMI) SN - 1552-5279 UR - https://doi.org/10.1016/j.jalz.2018.06.3053 N1 - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions. IS - 12 SP - 1623 VL - 14 ER -